Y-mabs suffers 16-0 defeat at FDA vote
![Photo: Kelly Davidson Photography](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14539396.ece/ALTERNATES/schema-16_9/doc7nevpthxk7p6zzynk0r.jpg)
The result of a vote at the FDA advisory committee on Y-mabs’ candidate omburtamab was clear:
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Y-mabs partner seeks launch of cancer drug in Brazil
For subscribers